{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:27:12Z","timestamp":1775860032567,"version":"3.50.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The study aimed at exploring the adverse events following immunization (AEFI) and their incidences among health workers in three different districts of central and western Nepal following the first dose of Covishield vaccine,. It also aimed at studying the association of AEFI with demographic and clinical characteristics of vaccinees, pre-vaccination anxiety level and prior history of COVID-19 infection (RT- PCR confirmed) status.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>This was a cross-sectional study carried out via face-to-face or telephonic interview among 1006 health workers one week after receiving their first dose of the Covishield vaccine. Incidence of adverse events was calculated in percentage while Chi-square Test was used to check the association of AEFI with independent variables. Logistic regression was used to find out the adjusted odd\u2019s ratio at 95% CI.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Incidence of AEFI was 79.8% with local and systemic AEFI being 68.0% and 59.7% respectively. Injection site tenderness was the commonest manifestation. Local and systemic symptoms resolved in less than one week among 96.8% and 98.7% vaccinees respectively. Females were more likely to develop AEFI than males (AOR = 1.7, 95% CI = 1.2\u20132.4). Vaccinees aged 45\u201359 years were 50% less likely to develop AEFI as compared to those aged less than 30 years (AOR 0.5, 95% CI = 0.3\u20130.8). Most of the vaccinees had not undergone RT-PCR testing for COVID-19 (59.8%). Those who were not tested for COVID-19 prior were 1.5 odds more likely to develop AEFI compared to those who were negative (AOR = 1.5, 95% CI = 1.1\u20132.1).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>More than two-third of the vaccinees developed one or more forms of adverse events, but most events were self-limiting. Females and young adults were more prone to develop AEFI.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0260638","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T18:38:44Z","timestamp":1640111924000},"page":"e0260638","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study"],"prefix":"10.1371","volume":"16","author":[{"given":"Prativa","family":"Subedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2195-9152","authenticated-orcid":true,"given":"Gopal Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binod","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajjwal","family":"Pyakurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"pone.0260638.ref001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"B Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"pone.0260638.ref002","first-page":"157","article-title":"WHO declares COVID-19 a pandemic.","volume":"91","author":"D Cucinotta","year":"2020","journal-title":"Acta Biomedica"},{"key":"pone.0260638.ref003","unstructured":"WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Available from: https:\/\/covid19.who.int\/."},{"key":"pone.0260638.ref004","unstructured":"Nepal: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data Available from: https:\/\/covid19.who.int\/region\/searo\/country\/np."},{"issue":"7","key":"pone.0260638.ref005","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2213-2600(21)00208-3","article-title":"From lockdown to vaccines: challenges and response in Nepal during the COVID-19 pandemic","volume":"9","author":"S Kansakar","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0260638.ref006","unstructured":"COVID-19 and hygiene in Nepal | WaterAid Global. Available from: https:\/\/www.wateraid.org\/global-covid-19-response\/nepal."},{"key":"pone.0260638.ref007","doi-asserted-by":"crossref","first-page":"597808","DOI":"10.3389\/fpubh.2021.597808","article-title":"How Well the Government of Nepal Is Responding to COVID-19? An Experience From a Resource-Limited Country to Confront Unprecedented Pandemic.","volume":"9","author":"B Rayamajhee","year":"2021","journal-title":"Front Public Heal."},{"key":"pone.0260638.ref008","doi-asserted-by":"crossref","first-page":"10003","DOI":"10.7189\/jogh.11.10003","article-title":"Current COVID-19 treatments: Rapid review of the literature.","volume":"11","author":"Y Dong","year":"2021","journal-title":"J Glob Health."},{"key":"pone.0260638.ref009","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3389\/fimmu.2020.01817","article-title":"The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.","volume":"11","author":"LSF Frederiksen","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"pone.0260638.ref010","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.3389\/fimmu.2020.586781","article-title":"Is Herd Immunity Against SARS-CoV-2 a Silver Lining?","volume":"11","author":"R Vignesh","year":"2020","journal-title":"Frontiers in Immunology."},{"issue":"7840","key":"pone.0260638.ref011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","article-title":"The lightning-fast quest for COVID vaccines\u2014and what it means for other diseases","volume":"589","author":"P. Ball","year":"2021","journal-title":"Nature"},{"key":"pone.0260638.ref012","unstructured":"WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. Available from: https:\/\/www.who.int\/news\/item\/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access."},{"key":"pone.0260638.ref013","unstructured":"U.K. Approves Pfizer Coronavirus Vaccine, a First in the West\u2014The New York Times. Available from: https:\/\/www.nytimes.com\/2020\/12\/02\/world\/europe\/pfizer-coronavirus-vaccine-approved-uk.html."},{"key":"pone.0260638.ref014","unstructured":"Vaccines\u2013COVID19 Vaccine Tracker. Available from: https:\/\/covid19.trackvaccines.org\/vaccines\/."},{"key":"pone.0260638.ref015","unstructured":"COVID-19 vaccine doses by country. Statista. Available from: https:\/\/www.statista.com\/statistics\/1194934\/number-of-covid-vaccine-doses-administered-by-county-worldwide\/."},{"key":"pone.0260638.ref016","article-title":"COVID-19 vaccine efficacy and effectiveness-the elephant (not) in the room.","author":"P Olliaro","year":"2021","journal-title":"The Lancet Microbe"},{"key":"pone.0260638.ref017","first-page":"1","article-title":"A million-dose success for Nepal: insights from Nepal\u2019s national vaccine deployment plan against COVID-19.","volume":"2021","author":"S Bhattarai","year":"2021","journal-title":"J Travel Med."},{"key":"pone.0260638.ref018","first-page":"1","article-title":"COVID-19: Insights into potential vaccines.","volume":"15","author":"KY Loo","year":"2021","journal-title":"Microorganisms"},{"key":"pone.0260638.ref019","article-title":"The \u2018Vero Cell\u2019 COVID-19 vaccine rollout in Nepal: What we know about the Chinese vaccine development and access?","author":"N Shah Jay","journal-title":"Journal of Patan Academy of Health Sciences."},{"key":"pone.0260638.ref020","unstructured":"Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria\u2122, SII COVISHIELD\u2122). Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1."},{"key":"pone.0260638.ref021","article-title":"Reactogenicity following Receipt of mRNA-Based COVID-19 Vaccines.","author":"J Chapin-Bardales","year":"2021","journal-title":"JAMA\u2014Journal of the American Medical Association."},{"key":"pone.0260638.ref022","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.","author":"C Menni","year":"2021","journal-title":"Lancet Infect Dis."},{"issue":"17","key":"pone.0260638.ref023","first-page":"e114","article-title":"Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.","volume":"36","author":"M Jeon","year":"2021"},{"issue":"1","key":"pone.0260638.ref024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3126\/jpahs.v8i1.36242","article-title":"Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine from in the first phase of vaccine roll out in Nepal.","volume":"8","author":"Shrijana Shrestha","year":"2021","journal-title":"Journal of Patan Academy of Health Sciences"},{"issue":"8","key":"pone.0260638.ref025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10654-020-00671-y","article-title":"Vaccine hesitancy: the next challenge in the fight against COVID-19","volume":"35","author":"AA Dror","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"pone.0260638.ref026","unstructured":"Situation Update #41\u2014Coronavirus Disease 2019 (COVID-19) WHO Country Office for Nepal. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/nepal-documents\/novel-coronavirus\/who-nepal-sitrep\/-41_weekly-who-nepal-situation-updates.pdf?sfvrsn=85f688d_5."},{"issue":"15","key":"pone.0260638.ref027","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.3346\/jkms.2021.36.e110","article-title":"Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers.","volume":"36","author":"JY Song","year":"2021","journal-title":"J Korean Med Sci."},{"key":"pone.0260638.ref028","doi-asserted-by":"crossref","first-page":"101989","DOI":"10.1016\/j.tmaid.2021.101989","article-title":"AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal.","volume":"40","author":"R Sah","year":"2021","journal-title":"Travel Medicine and Infectious Disease."},{"key":"pone.0260638.ref029","article-title":"The initial experience of COVID-19 vaccination from a tertiary care centre of India.","author":"COVID-Vaccination Group S","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"pone.0260638.ref030","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0260638.ref031","doi-asserted-by":"crossref","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study","volume":"373","author":"A Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"pone.0260638.ref032","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"J. Wise","year":"2021","journal-title":"BMJ"},{"issue":"10267","key":"pone.0260638.ref033","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial.","volume":"396","author":"MN Ramasamy","year":"2020","journal-title":"The Lancet"},{"key":"pone.0260638.ref034","article-title":"Survey of symptoms following COVID-19 vaccination in India.","author":"R Jayadevan","year":"2021","journal-title":"medRxiv."},{"issue":"6","key":"pone.0260638.ref035","first-page":"408","article-title":"Sex and Gender Impact Immune Responses to Vaccines Among the Elderly.","volume":"30","author":"A. L. Fink","year":"2015","journal-title":"Physiology (Bethesda)."},{"issue":"1","key":"pone.0260638.ref036","first-page":"1","article-title":"Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females","volume":"4","author":"T Potluri","year":"2019","journal-title":"npj Vaccines"},{"key":"pone.0260638.ref037","article-title":"Adverse events and their association with comorbidities after first and second doses of Covishield vaccination among healthcare workers of Government owned medical colleges in Kerala.","author":"T Mathew","year":"2021","journal-title":"medRxiv"},{"issue":"3","key":"pone.0260638.ref038","doi-asserted-by":"crossref","first-page":"136","DOI":"10.25100\/cm.v45i3.1711","article-title":"Considerations on immunization: Anxiety-related reactions in clusters.","volume":"45","author":"R. Palacios","year":"2014","journal-title":"Colomb Med (Cali)."},{"issue":"8","key":"pone.0260638.ref039","doi-asserted-by":"crossref","first-page":"e2122255","DOI":"10.1001\/jamanetworkopen.2021.22255","volume":"4","author":"R Shavit","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T18:39:38Z","timestamp":1640111978000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260638"}},"subtitle":[],"editor":[{"given":"Walter RJ","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260638","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}